首页 > 最新文献

Pharmacology & Pharmacy最新文献

英文 中文
DEVELOPMENT OF MICROCAPSULES BASED ON COMBINED ANTIDIABETIC SUBSTANCE: PHARMACOLOGICAL CHARACTERISTICS 联合降糖药微胶囊的研制:药理特性
Pub Date : 2022-10-29 DOI: 10.19163/2307-9266-2022-10-4-320-330
A. Giyoszoda, E. Stepanova, O. Veselova, S. E. Storozhenko
The comparative assessment results of the hypoglycemic activity of a combined preparation containing microcapsules with a phytocomposition consisting of Glycyrrhiza glabra L. extracts, a dry extract of Galega officinalis L., Mentha piperita L., and gliclazide, are discussed in the article. Methods for obtaining microcapsules with an original PEG-6000 shell are described.The aim of the study was to develop an optimal technology for obtaining microcapsules with a PEG-6000 shell containing a combined antidiabetic substance, and conduct its detailed pharmacological study on the model of type 2 diabetes mellitus, to conduct a detailed comparative pharmacological study of a microencapsulated antidiabetic composition with a shell based on PEG-6000, including gliclazide and a sum of phytoextracts on the model of type 2 diabetes mellitus.Materials and methods. As the main objects of the study, microcapsules with a PEG-6000 shell were obtained using methyl miristate as the base liquid. The capsules contained the amount of plant extracts in their composition: a dry extract of Glycyrrhiza glabra L., a dry extract of Galega officinalis L., a dry extract of Mentha piperita L., and gliclazide. The study of a hypoglycemic activity was carried out after a single administration of drugs to the animals with alloxan-induced type 2 diabetes mellitus. The cumulative effect assessment of the drugs was carried out within 14 days with a test for the resistance to oral glucose on days 7 and 14.Results. Microcapsules with the original shell were obtained by dispersion in a liquid-liquid system with the adjustment of some technological stages. The effect of the drugs under study on the glycemic profile in the rats with an experimental model of type 2 diabetes mellitus was investigated. A comparative evaluation of the pharmacological effect was carried out with a separate and combined use of microencapsulated preparations.Conclusion. The rationality of combining phytocomponents and a synthetic antidiabetic agent in microcapsules has been proven. The obtained results testify to the rationality of plant extracts combination and a synthetic hypoglycemic agent – gliclazide in microcapsules.
本文讨论了由甘草酸提取物、甘露皂苷干提取物、薄荷和格列齐特组成的微胶囊联合制剂的降糖活性的比较评价结果。描述了用原始PEG-6000外壳制备微胶囊的方法。本研究的目的是开发一种获得含有联合抗糖尿病物质PEG-6000壳微胶囊的最佳工艺,并对其进行2型糖尿病模型的详细药理学研究,对基于PEG-6000壳的微胶囊抗糖尿病组合物进行详细的药理学比较研究,包括格列西特和一定数量的植物提取物对2型糖尿病模型的影响。材料和方法。以miristate甲酯为底液,制备了具有PEG-6000外壳的微胶囊。胶囊的成分中含有一定数量的植物提取物:甘草酸干提取物、甘露酸干提取物、薄荷酸干提取物和格列齐特。研究了四氧嘧啶诱导的2型糖尿病动物单次用药后的降糖活性。在14天内进行药物累积效应评价,并在第7天和第14天进行口服葡萄糖抵抗试验。通过调整工艺步骤,在液-液体系中分散得到了具有原壳的微胶囊。研究了所研究药物对2型糖尿病大鼠血糖谱的影响。对微胶囊制剂单独使用和联合使用的药理效果进行了比较评价。证实了植物成分与合成抗糖尿病药在微胶囊中结合的合理性。实验结果证实了植物提取物组合及合成的降血糖剂格列齐特微胶囊的合理性。
{"title":"DEVELOPMENT OF MICROCAPSULES BASED ON COMBINED ANTIDIABETIC SUBSTANCE: PHARMACOLOGICAL CHARACTERISTICS","authors":"A. Giyoszoda, E. Stepanova, O. Veselova, S. E. Storozhenko","doi":"10.19163/2307-9266-2022-10-4-320-330","DOIUrl":"https://doi.org/10.19163/2307-9266-2022-10-4-320-330","url":null,"abstract":"The comparative assessment results of the hypoglycemic activity of a combined preparation containing microcapsules with a phytocomposition consisting of Glycyrrhiza glabra L. extracts, a dry extract of Galega officinalis L., Mentha piperita L., and gliclazide, are discussed in the article. Methods for obtaining microcapsules with an original PEG-6000 shell are described.The aim of the study was to develop an optimal technology for obtaining microcapsules with a PEG-6000 shell containing a combined antidiabetic substance, and conduct its detailed pharmacological study on the model of type 2 diabetes mellitus, to conduct a detailed comparative pharmacological study of a microencapsulated antidiabetic composition with a shell based on PEG-6000, including gliclazide and a sum of phytoextracts on the model of type 2 diabetes mellitus.Materials and methods. As the main objects of the study, microcapsules with a PEG-6000 shell were obtained using methyl miristate as the base liquid. The capsules contained the amount of plant extracts in their composition: a dry extract of Glycyrrhiza glabra L., a dry extract of Galega officinalis L., a dry extract of Mentha piperita L., and gliclazide. The study of a hypoglycemic activity was carried out after a single administration of drugs to the animals with alloxan-induced type 2 diabetes mellitus. The cumulative effect assessment of the drugs was carried out within 14 days with a test for the resistance to oral glucose on days 7 and 14.Results. Microcapsules with the original shell were obtained by dispersion in a liquid-liquid system with the adjustment of some technological stages. The effect of the drugs under study on the glycemic profile in the rats with an experimental model of type 2 diabetes mellitus was investigated. A comparative evaluation of the pharmacological effect was carried out with a separate and combined use of microencapsulated preparations.Conclusion. The rationality of combining phytocomponents and a synthetic antidiabetic agent in microcapsules has been proven. The obtained results testify to the rationality of plant extracts combination and a synthetic hypoglycemic agent – gliclazide in microcapsules.","PeriodicalId":20031,"journal":{"name":"Pharmacology & Pharmacy","volume":"26 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75711723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
EVALUATION OF PLANT-BASED UV FILTERS POTENTIAL IN MODERN CONCEPT VIEW OF SKIN PHOTOPROTECTION 从现代皮肤光防护的角度评价植物基紫外线过滤器的潜力
Pub Date : 2022-10-29 DOI: 10.19163/2307-9266-2022-10-4-308-319
O. D. Nemyatykh, I. I. Terninko, A. Sabitov, A. I. Lyashko, Z. Sakipova
A therapeutic plants potential is based on the pharmacological effects due to their phytochemical profile. Today, scientific interest in botanicals is increasing as a result of recent research that looks at the prospect of using these raw materials for the cosmetic industry as a means to protect the skin from the harmful effects of UV rays.The aim of the study was to evaluate a potential of plant-based UV-filters in modern concept view of skin photoprotection.Materials and methods. A systematic literature search was carried out using the electronic information arrays PubMed, Scopus, Google Scholar, eLibrary. The search depth was 10 years (the period from 2010 to 2021). The search was carried out by the following keywords: antioxidants, cosmetics, photoprotection, chemical composition, pharmacological action.Results. In the paper, modern principles of skin photoprotection based on the use of chemical or physical UV-filters are considered and scientifically substantiated A trend for the use of plant-based materials and their components in the formulation of photoprotectors was notified. That is associated with a wide activity spectrum, the absence of a xenobiotic effect, and a high bioavailability of organic plant compounds.Conclusion. The data analysis from scientific publications demonstrated a potential photoprotective activity of plant-based biologically active substances due to antioxidant, anti-inflammatory and anti-radical effects. The results of the study are a theoretical basis for a further comprehensive experimental study of plant objects in order to obtain a pool of evidence in the field of photoprotection in in vivo experiments.
治疗植物的潜力是基于其药理作用,由于它们的植物化学特征。今天,由于最近的研究,科学家对植物药的兴趣正在增加,这些研究着眼于将这些原料用于化妆品工业的前景,作为保护皮肤免受紫外线有害影响的一种手段。该研究的目的是评估植物基紫外线过滤器在现代皮肤光防护概念中的潜力。材料和方法。采用PubMed、Scopus、Google Scholar、library等电子信息阵列进行系统文献检索。搜索深度为10年(2010年至2021年)。以抗氧化剂、化妆品、光防护、化学成分、药理作用等关键词进行检索。摘要现代皮肤光原理的基础上,利用化学或物理紫外线过滤被认为是和科学证实这一趋势使用植物性材料的配方及其组件photoprotectors通知。这与有机植物化合物的广谱活性、无异种效应和高生物利用度有关。来自科学出版物的数据分析表明,由于抗氧化、抗炎和抗自由基作用,植物性生物活性物质具有潜在的光保护活性。本研究结果为进一步对植物对象进行全面的实验研究提供了理论基础,以期在体内实验中获得光保护领域的证据库。
{"title":"EVALUATION OF PLANT-BASED UV FILTERS POTENTIAL IN MODERN CONCEPT VIEW OF SKIN PHOTOPROTECTION","authors":"O. D. Nemyatykh, I. I. Terninko, A. Sabitov, A. I. Lyashko, Z. Sakipova","doi":"10.19163/2307-9266-2022-10-4-308-319","DOIUrl":"https://doi.org/10.19163/2307-9266-2022-10-4-308-319","url":null,"abstract":"A therapeutic plants potential is based on the pharmacological effects due to their phytochemical profile. Today, scientific interest in botanicals is increasing as a result of recent research that looks at the prospect of using these raw materials for the cosmetic industry as a means to protect the skin from the harmful effects of UV rays.The aim of the study was to evaluate a potential of plant-based UV-filters in modern concept view of skin photoprotection.Materials and methods. A systematic literature search was carried out using the electronic information arrays PubMed, Scopus, Google Scholar, eLibrary. The search depth was 10 years (the period from 2010 to 2021). The search was carried out by the following keywords: antioxidants, cosmetics, photoprotection, chemical composition, pharmacological action.Results. In the paper, modern principles of skin photoprotection based on the use of chemical or physical UV-filters are considered and scientifically substantiated A trend for the use of plant-based materials and their components in the formulation of photoprotectors was notified. That is associated with a wide activity spectrum, the absence of a xenobiotic effect, and a high bioavailability of organic plant compounds.Conclusion. The data analysis from scientific publications demonstrated a potential photoprotective activity of plant-based biologically active substances due to antioxidant, anti-inflammatory and anti-radical effects. The results of the study are a theoretical basis for a further comprehensive experimental study of plant objects in order to obtain a pool of evidence in the field of photoprotection in in vivo experiments.","PeriodicalId":20031,"journal":{"name":"Pharmacology & Pharmacy","volume":"66 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84012283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
INTERRELATION BETWEEN MITOCHONDRIAL ENZYME ACTIVITY AND ANTIOXIDANT ACTIVITY OF SECONDARY POLYPHENOL NATURE METABOLITES IN HEMIPARASITE VISCUM ALBUM L. LEAVES 半寄生虫粘属植物叶片线粒体酶活性与次生多酚代谢产物抗氧化活性的关系
Pub Date : 2022-10-29 DOI: 10.19163/2307-9266-2022-10-4-343-353
S. Adzhiakhmetova, D. Pozdnyakov, N. Chervonnaya, E. O. Kulichenko, E. Oganesyan
Antioxidants are widely used in practical medicine. Not only the search for new plant antioxidants, but also the study of the factors affecting their accumulation in plants, are relevant.The aim is to study the interrelation between the activity of mitochondrial enzymes and the antioxidant activity of the secondary polyphenolic nature metabolites in hemiparasite Viscum Album L. leaves.Materials and methods. The sampling material was Viscum album L. leaves, collected in winter from a host tree, Malus domestica Borkh. The extraction of biologically active substances was carried out with ethyl alcohol of various concentrations (90%, 70% and 50%), or purified water. The amount of total antioxidants was estimated by the amperometric method. The amount of total phenols was evaluated in the reaction with the Folin-Ciocalteu reagent. The concentration of total flavonoids was estimated by the change in the optical density of the rutin with aluminum (III) chloride complex. The antioxidant properties of the analyzed extracts were determined in vitro in the induced lipid peroxidation test. The activity of aconitase was assessed by a conjugated aconitase-isocitrate dehydrogenase reaction, citrate synthase – by changing the color intensity of the Ellman reagent solution, succinate dehydrogenase were determined in the reaction of succinate-dependent oxidation of 2,6-dichlorophenolindophenol.Results. The carried out study showed that the maximum amount of total phenols (2.39±0.05%) is observed in a 50% ethanol extract from Viscum album L. leaves, with the content of total flavonoids equal to 1.83±0.04%, and the antioxidants equal to 0.503±0.007 mg/g (a quercetin equivalent) and 0.322±0.006 mg/g (a gallic acid equivalent). A 50% ethanol extract suppressed lipid peroxidation in the model mixture with IC50=106.3±1.09 µg/ml. In Viscum album L. leaves, a high activity of aconitase which strongly correlated (r=0.88416) with changes in the concentration of flavonoids, has been notified.Conclusion. The optimal extractant for obtaining extracts with a high antioxidant activity is 50% ethyl alcohol. The analysis of the mitochondrial enzymes activity showed that in Viscum album L. leaves collected in winter, a high activity of aconitase strongly correlated with changes in the concentration of flavonoids (r=0.88416).
抗氧化剂在实际医学中应用广泛。不仅是寻找新的植物抗氧化剂,而且对其在植物体内积累的影响因素的研究也具有重要意义。目的是研究半寄生虫粘属植物叶片线粒体酶活性与次生多酚代谢产物抗氧化活性之间的相互关系。材料和方法。取样材料为冬季从寄主树海棠(Malus domestica Borkh)上采集的visum album L.叶片。用不同浓度的乙醇(90%、70%和50%)或纯净水提取生物活性物质。用安培法测定了总抗氧化剂的含量。用Folin-Ciocalteu试剂测定了总酚的含量。通过测定芦丁与氯化铝络合物的光密度变化来测定总黄酮的浓度。通过体外诱导脂质过氧化实验测定所分析提取物的抗氧化性能。采用共轭乌头酸-异柠檬酸脱氢酶反应测定乌头酸酶活性,通过改变elman试剂溶液颜色强度测定枸橼酸合酶活性,测定琥珀酸依赖2,6-二氯酚吲哚酚氧化反应中琥珀酸脱氢酶活性。研究结果表明,50%乙醇提取物中总酚含量最高,为2.39±0.05%,总黄酮含量为1.83±0.04%,抗氧化剂含量为0.503±0.007 mg/g(槲皮素当量)和0.322±0.006 mg/g(没食子酸当量)。50%乙醇提取物抑制模型混合物脂质过氧化,IC50=106.3±1.09µg/ml。结果表明,乌头酸酶活性较高,与黄酮浓度变化呈显著正相关(r=0.88416)。获得高抗氧化活性提取物的最佳萃取剂为50%乙醇。线粒体酶活性分析表明,冬采粘子叶片中乌头酸酶活性高与黄酮浓度变化呈极显著相关(r=0.88416)。
{"title":"INTERRELATION BETWEEN MITOCHONDRIAL ENZYME ACTIVITY AND ANTIOXIDANT ACTIVITY OF SECONDARY POLYPHENOL NATURE METABOLITES IN HEMIPARASITE VISCUM ALBUM L. LEAVES","authors":"S. Adzhiakhmetova, D. Pozdnyakov, N. Chervonnaya, E. O. Kulichenko, E. Oganesyan","doi":"10.19163/2307-9266-2022-10-4-343-353","DOIUrl":"https://doi.org/10.19163/2307-9266-2022-10-4-343-353","url":null,"abstract":"Antioxidants are widely used in practical medicine. Not only the search for new plant antioxidants, but also the study of the factors affecting their accumulation in plants, are relevant.The aim is to study the interrelation between the activity of mitochondrial enzymes and the antioxidant activity of the secondary polyphenolic nature metabolites in hemiparasite Viscum Album L. leaves.Materials and methods. The sampling material was Viscum album L. leaves, collected in winter from a host tree, Malus domestica Borkh. The extraction of biologically active substances was carried out with ethyl alcohol of various concentrations (90%, 70% and 50%), or purified water. The amount of total antioxidants was estimated by the amperometric method. The amount of total phenols was evaluated in the reaction with the Folin-Ciocalteu reagent. The concentration of total flavonoids was estimated by the change in the optical density of the rutin with aluminum (III) chloride complex. The antioxidant properties of the analyzed extracts were determined in vitro in the induced lipid peroxidation test. The activity of aconitase was assessed by a conjugated aconitase-isocitrate dehydrogenase reaction, citrate synthase – by changing the color intensity of the Ellman reagent solution, succinate dehydrogenase were determined in the reaction of succinate-dependent oxidation of 2,6-dichlorophenolindophenol.Results. The carried out study showed that the maximum amount of total phenols (2.39±0.05%) is observed in a 50% ethanol extract from Viscum album L. leaves, with the content of total flavonoids equal to 1.83±0.04%, and the antioxidants equal to 0.503±0.007 mg/g (a quercetin equivalent) and 0.322±0.006 mg/g (a gallic acid equivalent). A 50% ethanol extract suppressed lipid peroxidation in the model mixture with IC50=106.3±1.09 µg/ml. In Viscum album L. leaves, a high activity of aconitase which strongly correlated (r=0.88416) with changes in the concentration of flavonoids, has been notified.Conclusion. The optimal extractant for obtaining extracts with a high antioxidant activity is 50% ethyl alcohol. The analysis of the mitochondrial enzymes activity showed that in Viscum album L. leaves collected in winter, a high activity of aconitase strongly correlated with changes in the concentration of flavonoids (r=0.88416).","PeriodicalId":20031,"journal":{"name":"Pharmacology & Pharmacy","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72670118","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
ADAPTATION OF “DRIED BLOOD DROP” METHOD FOR THERAPEUTIC DRUG MONITORING “干血滴法”在治疗药物监测中的应用
Pub Date : 2022-10-29 DOI: 10.19163/2307-9266-2022-10-4-331-342
V. Petrov, I. S. Anikeev, T. Zayachnikova, A. Strygin, A. M. Dotsenko
To control the concentration of drugs with a narrow therapeutic range, and to conduct effective and safe treatments, Therapeutic Drug Monitoring (TDM) is carried out. However, to date, the implementation of TDM is associated with various difficulties, for the solution of which more convenient and less invasive methods for collecting biological material are being developed.The aim of the study was to develop protocols for the collection and storage of “dried blood spot” (DBS) samples, as well as protocols for the validation methods for the quantitative determination of drugs in whole blood, using this technology for subsequent therapeutic drug monitoring.Materials and methods. To analyze a “dried blood spot” method in detail and to identify the characteristic features of taking and storing biosamples, a collection and analysis of scientific literature over the past 10 years has been conducted. The search for literature materials has been carried out from open and accessible sources located in the scientific libraries of institutions, in electronic databases and search engines: Elibrary, PubMed, Scopus, Cyberleninka, Medline, ScienceDirect, Web of Science, Google Scholar. Primary protocols for taking, storing and analyzing samples of the “dried blood drop” have been prepared. To obtain the adequate quality samples, the developed protocols have been tested and optimized at the stages of selection and storage. By high-performance liquid chromatography with mass spectrometric detection (HPLC-MS/MS), using a “dried blood drop” as a sample preparation, drug validation protocols have been optimized to ensure that acceptable validation characteristics were achieved, and subsequent Therapeutic Drug Monitoring was performed.Results. The features of the collection, storage and analysis of the “dried blood spot” samples have been revealed. Such characteristics as a spot volume effect, a hematocrit effect, a droplet uniformity, which can affect the results of a quantitative HPLC-MS/MS analysis, have been determined. For a successful use of the new methods, appropriate protocols for taking samples of “dried blood spot” from the finger of adult patients and from the heel of newborns, as well as protocols for validating methods for the quantitative determination of drugs from these samples, have been developed.Conclusion. The application of the “dried blood spot” method using newly developed protocols for taking, storing and analyzing biological samples, relieves the existing constraints in conducting TDM, and can later become a promising method for conducting preclinical and clinical studies.
治疗药物监测(therapeutic Drug Monitoring, TDM)是为了控制治疗范围较窄的药物浓度,进行有效、安全的治疗。然而,迄今为止,TDM的实施伴随着各种困难,为了解决这些困难,正在开发更方便和更少侵入性的生物材料收集方法。本研究的目的是制定“干血斑”(DBS)样本的收集和储存方案,以及全血中药物定量测定的验证方法的方案,并利用该技术进行后续治疗药物监测。材料和方法。为了详细分析“干血点”法,并确定生物样本采集和储存的特点,对近10年的科学文献进行了收集和分析。文献资料的搜索是从机构的科学图书馆、电子数据库和搜索引擎(图书馆、PubMed、Scopus、Cyberleninka、Medline、ScienceDirect、Web of Science、Google Scholar)中开放和可访问的资源中进行的。已经制定了采集、储存和分析“干血滴”样本的主要方案。为了获得足够质量的样品,在选择和储存阶段对所开发的方案进行了测试和优化。通过高效液相色谱-质谱检测(HPLC-MS/MS),使用“干血滴”作为样品制备,优化了药物验证方案,以确保获得可接受的验证特性,并进行了后续的治疗药物监测。揭示了“干血斑”标本的采集、保存和分析特点。斑点体积效应、红细胞压积效应、液滴均匀性等特性会影响定量HPLC-MS/MS分析的结果,这些特性已经确定。为确保新方法的成功应用,已经制定了从成人患者手指和新生儿脚跟采集“干血斑”样本的适当方案,以及从这些样本中验证药物定量测定方法的方案。“干血斑”法采用新开发的生物样本采集、储存和分析方案,缓解了目前进行TDM的限制,以后可能成为进行临床前和临床研究的一种有前景的方法。
{"title":"ADAPTATION OF “DRIED BLOOD DROP” METHOD FOR THERAPEUTIC DRUG MONITORING","authors":"V. Petrov, I. S. Anikeev, T. Zayachnikova, A. Strygin, A. M. Dotsenko","doi":"10.19163/2307-9266-2022-10-4-331-342","DOIUrl":"https://doi.org/10.19163/2307-9266-2022-10-4-331-342","url":null,"abstract":"To control the concentration of drugs with a narrow therapeutic range, and to conduct effective and safe treatments, Therapeutic Drug Monitoring (TDM) is carried out. However, to date, the implementation of TDM is associated with various difficulties, for the solution of which more convenient and less invasive methods for collecting biological material are being developed.The aim of the study was to develop protocols for the collection and storage of “dried blood spot” (DBS) samples, as well as protocols for the validation methods for the quantitative determination of drugs in whole blood, using this technology for subsequent therapeutic drug monitoring.Materials and methods. To analyze a “dried blood spot” method in detail and to identify the characteristic features of taking and storing biosamples, a collection and analysis of scientific literature over the past 10 years has been conducted. The search for literature materials has been carried out from open and accessible sources located in the scientific libraries of institutions, in electronic databases and search engines: Elibrary, PubMed, Scopus, Cyberleninka, Medline, ScienceDirect, Web of Science, Google Scholar. Primary protocols for taking, storing and analyzing samples of the “dried blood drop” have been prepared. To obtain the adequate quality samples, the developed protocols have been tested and optimized at the stages of selection and storage. By high-performance liquid chromatography with mass spectrometric detection (HPLC-MS/MS), using a “dried blood drop” as a sample preparation, drug validation protocols have been optimized to ensure that acceptable validation characteristics were achieved, and subsequent Therapeutic Drug Monitoring was performed.Results. The features of the collection, storage and analysis of the “dried blood spot” samples have been revealed. Such characteristics as a spot volume effect, a hematocrit effect, a droplet uniformity, which can affect the results of a quantitative HPLC-MS/MS analysis, have been determined. For a successful use of the new methods, appropriate protocols for taking samples of “dried blood spot” from the finger of adult patients and from the heel of newborns, as well as protocols for validating methods for the quantitative determination of drugs from these samples, have been developed.Conclusion. The application of the “dried blood spot” method using newly developed protocols for taking, storing and analyzing biological samples, relieves the existing constraints in conducting TDM, and can later become a promising method for conducting preclinical and clinical studies.","PeriodicalId":20031,"journal":{"name":"Pharmacology & Pharmacy","volume":"26 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84287031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
EVALUATION OF WEIGHT REDUCTION EFFICACY AND SAFETY OF SIBUTRAMIN-CONTAINING DRUGS IN PATIENTS WITH ALIMENTARY OBESITY 评价含西布曲明药物对食源性肥胖患者的减肥效果和安全性
Pub Date : 2022-07-25 DOI: 10.19163/2307-9266-2022-10-3-289-304
T. Demidova, M. Y. Izmailova, S. E. Ushakova, K. Zaslavskaya, A. Odegova, V. V. Popova, M. E. Nevretdinova, A. Verbovoy, P. A. Bely
The article presents clinical study results of the efficacy and safety of combination therapy with sibutramine and metformin (fixed combination) in comparison with sibutramine therapy with microcrystalline cellulose in patients with alimentary obesity.The aim is to evaluate the efficacy and safety of using the sibutramine+metformin fixed dose combination (Reduxin® Forte) and compare it with the sibutramine + microcrystalline cellulose combination (Reduxin®) in patients with alimentary obesity in the course of the obesity therapy.Materials and methods. Male and female patients (240 people) aged 18 to 65 years inclusive with alimentary obesity, meeting the inclusion criteria and not meeting the non-inclusion criteria, were randomized into 2 groups in a 1:1 ratio. One group (n=120) received sibutramine+ metformin p. o., 1 tablet (850 mg + 10 mg) once per day, the second group (n=120) received sibutramine+ microcrystalline cellulose (MCC) p. o., 1 capsule (10 mg + 158.5 mg) once per day in the morning. On day 30 ± 1, in the absence of a 2 kg weight loss compared to the first visit, the dose was increased in accordance with the medical instruction. The therapy period was 180 days. The randomization list was generated by the factory method of random numbers. The efficacy and safety were assessed by anthropometric, clinical and laboratory parameters and the SF-36 questionnaire. The proportion of patients who achieved a decrease in body weight by more than 5% in 6 months, the magnitude and dynamics of changes in body weight and body mass index, waist and hip measurements, their ratios, changes in lipid profile, blood pressure, as well as the total number of adverse events, their frequency and nature of occurrence were analyzed.Results. The both drugs have demonstrated efficacy in all parameters of the obesity therapy. At the same time, in a comparative analysis, a statistically significant advantage of therapy with sibutramine + metformin was demonstrated in relation to the proportion of patients who had achieved more than 5% weight loss (body weight dynamics). Significant benefits were shown in terms of the magnitude of the change in body mass index (BMI); there was a statistically significant increase in the proportion of the patients who had switched from one category of BMI to another. By the end of the study, the vast majority of patients had no longer met the criteria for the diagnosis of “Obesity”. There was also a statistically significant benefit of sibutramine + metformin in terms of lowering triglycerides and low-density lipoprotein levels. The analysis of the safety parameters of sibutramine + metformin confirms a high safety profile of the drug, a comparative statistical analysis of adverse events in terms of their presence, severity, causal relationship with therapy and outcome have not revealed intergroup differences. Adverse events were transient and did not require discontinuation of therapy.Conclusion. The results of the study showed th
本文介绍西布曲明联合二甲双胍(固定联合)与西布曲明联合微晶纤维素治疗食源性肥胖患者的疗效和安全性的临床研究结果。目的是评价西布曲明+二甲双胍固定剂量联合治疗(Reduxin®Forte)的疗效和安全性,并将其与西布曲明+微晶纤维素联合治疗(Reduxin®)在食性肥胖患者的肥胖治疗过程中进行比较。材料和方法。年龄18 ~ 65岁,伴有食源性肥胖,符合和不符合纳入标准的患者240例,按1:1的比例随机分为两组。第一组(n=120)给予西布曲明+二甲双胍口服1片(850 mg + 10 mg),每天1次;第二组(n=120)给予西布曲明+微晶纤维素(MCC)口服1粒(10 mg + 158.5 mg),每天早晨1次。在第30±1天,在与第一次就诊相比体重没有减轻2 kg的情况下,按照医疗指示增加剂量。治疗期为180 d。随机化列表采用随机数出厂法生成。通过人体测量、临床和实验室参数及SF-36问卷评估疗效和安全性。分析6个月内体重下降5%以上的患者比例、体重、体质指数、腰围、臀围的变化幅度和动态、比例、血脂、血压的变化,以及不良事件的总次数、发生频率和性质。这两种药物在肥胖治疗的所有参数中都显示出疗效。同时,在一项比较分析中,西布曲明+二甲双胍治疗在体重减轻超过5%的患者比例(体重动态)方面具有统计学上显著的优势。在身体质量指数(BMI)的变化幅度方面显示出显著的益处;从统计数据来看,从一种BMI类型切换到另一种BMI类型的患者比例显著增加。到研究结束时,绝大多数患者不再符合“肥胖”的诊断标准。在降低甘油三酯和低密度脂蛋白水平方面,西布曲明+二甲双胍在统计学上也有显著的益处。西布曲明+二甲双胍的安全性参数分析证实了该药的高安全性,对不良事件的存在、严重程度、与治疗的因果关系和结局的比较统计分析未发现组间差异。不良事件是短暂的,不需要停止治疗。研究结果表明,用Reduxin®和Reduxin®Forte治疗可显著降低体重。然而,使用固定组合对血脂和患者生活质量具有更有效的积极作用,这与高安全性相结合,证明了使用Reduxin®Forte治疗肥胖和恢复代谢健康的可能性和方便性,即使在没有额外碳水化合物代谢紊乱的患者中也是如此。
{"title":"EVALUATION OF WEIGHT REDUCTION EFFICACY AND SAFETY OF SIBUTRAMIN-CONTAINING DRUGS IN PATIENTS WITH ALIMENTARY OBESITY","authors":"T. Demidova, M. Y. Izmailova, S. E. Ushakova, K. Zaslavskaya, A. Odegova, V. V. Popova, M. E. Nevretdinova, A. Verbovoy, P. A. Bely","doi":"10.19163/2307-9266-2022-10-3-289-304","DOIUrl":"https://doi.org/10.19163/2307-9266-2022-10-3-289-304","url":null,"abstract":"The article presents clinical study results of the efficacy and safety of combination therapy with sibutramine and metformin (fixed combination) in comparison with sibutramine therapy with microcrystalline cellulose in patients with alimentary obesity.The aim is to evaluate the efficacy and safety of using the sibutramine+metformin fixed dose combination (Reduxin® Forte) and compare it with the sibutramine + microcrystalline cellulose combination (Reduxin®) in patients with alimentary obesity in the course of the obesity therapy.Materials and methods. Male and female patients (240 people) aged 18 to 65 years inclusive with alimentary obesity, meeting the inclusion criteria and not meeting the non-inclusion criteria, were randomized into 2 groups in a 1:1 ratio. One group (n=120) received sibutramine+ metformin p. o., 1 tablet (850 mg + 10 mg) once per day, the second group (n=120) received sibutramine+ microcrystalline cellulose (MCC) p. o., 1 capsule (10 mg + 158.5 mg) once per day in the morning. On day 30 ± 1, in the absence of a 2 kg weight loss compared to the first visit, the dose was increased in accordance with the medical instruction. The therapy period was 180 days. The randomization list was generated by the factory method of random numbers. The efficacy and safety were assessed by anthropometric, clinical and laboratory parameters and the SF-36 questionnaire. The proportion of patients who achieved a decrease in body weight by more than 5% in 6 months, the magnitude and dynamics of changes in body weight and body mass index, waist and hip measurements, their ratios, changes in lipid profile, blood pressure, as well as the total number of adverse events, their frequency and nature of occurrence were analyzed.Results. The both drugs have demonstrated efficacy in all parameters of the obesity therapy. At the same time, in a comparative analysis, a statistically significant advantage of therapy with sibutramine + metformin was demonstrated in relation to the proportion of patients who had achieved more than 5% weight loss (body weight dynamics). Significant benefits were shown in terms of the magnitude of the change in body mass index (BMI); there was a statistically significant increase in the proportion of the patients who had switched from one category of BMI to another. By the end of the study, the vast majority of patients had no longer met the criteria for the diagnosis of “Obesity”. There was also a statistically significant benefit of sibutramine + metformin in terms of lowering triglycerides and low-density lipoprotein levels. The analysis of the safety parameters of sibutramine + metformin confirms a high safety profile of the drug, a comparative statistical analysis of adverse events in terms of their presence, severity, causal relationship with therapy and outcome have not revealed intergroup differences. Adverse events were transient and did not require discontinuation of therapy.Conclusion. The results of the study showed th","PeriodicalId":20031,"journal":{"name":"Pharmacology & Pharmacy","volume":"28 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78184491","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
CLUSTER ANALYSIS OF INTEGRATED “DRUG SUPPLY” CONCEPT 整合“药品供应”概念的聚类分析
Pub Date : 2022-07-24 DOI: 10.19163/2307-9266-2022-10-3-232-243
G. S. Barkaev, T. I. Kabakova, A. Goryachev
The aim of the article is the structure and content specification of the subject area professional term “drug supply” in order to deepen and concretize the conceptual apparatus in the field of the pharmaceutical activity.Materials and methods. The review presents the analysis of 389 titles of scientific pharmaceutical publications for the periods of 1995–1998 and 2010–2019. The selection of publications was carried out by the random sampling based on the phrases: «drug provision», «medical care», «provision of medicines», «pharmaceutical care», «medicinal services», «drug supply» and their English-language counterparts in Russian and foreign electronic information sources. A methodological base of the study was a cluster analysis of the subject area concept of “drug supply” according to the methodology proposed by E.A. Korzhavykh and I.V. Voronovich. In this study, a cluster was interpreted as a set of publications in which a certain pair of terms was simultaneously cited with a preset frequency of co-citation.Results. When analyzing the publications, two clusters of the “drug supply” concept were formed for the time periods indicated above. The comparison of the clusters showed an increase in the activity of the scientific research to expand the structure and content of the subject area of the “drug supply” concept. For the modern cluster, 124 co – cited pairs of lexical units were selected. They were grouped into 9 hierarchy levels according to the strength of relationship between an interval of 10 units and mentioning frequencies of the “drug supply” term. At the final stage, a graphical model of the “drug supply” concept cluster was formed. It was established that the lexical units included from the first to the fifth level, are the cluster nucleus of the “drug supply” concept as the most stable part of the lexical array, which it is advisable to rely on when developing a definition for the concept under study.Conclusion. Thus, the subject field of the “drug supply” concept is characterized by the scientific research, reflecting the socio-economic significance of the objects under study in the field of pharmaceutical activities, and its content is characterized by a high level of pharmaceutical knowledge which describes the most stable elements that make it possible to formulate an adequate definition of the “drug supply” definition.
本文的目的是对学科领域专业术语“药品供应”的结构和内容进行规范,以深化和具体化药学活动领域的概念装置。材料和方法。该综述分析了1995-1998年和2010-2019年期间389篇药学科学出版物的标题。出版物的选择采用随机抽样的方法,根据下列词语进行选择:"药品供应"、"医疗保健"、"提供药品"、"医药保健"、"医疗服务"、"药品供应"及其对应的俄语和外国电子信息来源中的英文词语。这项研究的方法学基础是根据E.A. Korzhavykh和I.V. Voronovich提出的方法学对“药物供应”这一主题领域概念进行聚类分析。在本研究中,聚类被解释为一组出版物,其中某对术语以预设的共引频率同时被引用。在对出版物进行分析时,在上述期间形成了“药物供应”概念的两组。各集群间的比较表明,扩大“药品供应”概念学科领域结构和内容的科研活动有所增加。对于现代聚类,选择了124对共被引的词汇单位。根据10个单位的间隔与“药品供应”词提及频率之间的关系强弱,将其分为9个层次。最后,形成“药品供应”概念集群的图形模型。结果表明,从第1至第5层所包含的词汇单元是“药品供应”概念的簇核,是词汇数组中最稳定的部分,在为所研究的概念制定定义时,应以此为依据。因此,“药品供应”概念的主题领域以科学研究为特征,反映了所研究对象在药学活动领域的社会经济意义,其内容以高水平的药学知识为特征,这些知识描述了最稳定的要素,使制定“药品供应”定义成为可能。
{"title":"CLUSTER ANALYSIS OF INTEGRATED “DRUG SUPPLY” CONCEPT","authors":"G. S. Barkaev, T. I. Kabakova, A. Goryachev","doi":"10.19163/2307-9266-2022-10-3-232-243","DOIUrl":"https://doi.org/10.19163/2307-9266-2022-10-3-232-243","url":null,"abstract":"The aim of the article is the structure and content specification of the subject area professional term “drug supply” in order to deepen and concretize the conceptual apparatus in the field of the pharmaceutical activity.Materials and methods. The review presents the analysis of 389 titles of scientific pharmaceutical publications for the periods of 1995–1998 and 2010–2019. The selection of publications was carried out by the random sampling based on the phrases: «drug provision», «medical care», «provision of medicines», «pharmaceutical care», «medicinal services», «drug supply» and their English-language counterparts in Russian and foreign electronic information sources. A methodological base of the study was a cluster analysis of the subject area concept of “drug supply” according to the methodology proposed by E.A. Korzhavykh and I.V. Voronovich. In this study, a cluster was interpreted as a set of publications in which a certain pair of terms was simultaneously cited with a preset frequency of co-citation.Results. When analyzing the publications, two clusters of the “drug supply” concept were formed for the time periods indicated above. The comparison of the clusters showed an increase in the activity of the scientific research to expand the structure and content of the subject area of the “drug supply” concept. For the modern cluster, 124 co – cited pairs of lexical units were selected. They were grouped into 9 hierarchy levels according to the strength of relationship between an interval of 10 units and mentioning frequencies of the “drug supply” term. At the final stage, a graphical model of the “drug supply” concept cluster was formed. It was established that the lexical units included from the first to the fifth level, are the cluster nucleus of the “drug supply” concept as the most stable part of the lexical array, which it is advisable to rely on when developing a definition for the concept under study.Conclusion. Thus, the subject field of the “drug supply” concept is characterized by the scientific research, reflecting the socio-economic significance of the objects under study in the field of pharmaceutical activities, and its content is characterized by a high level of pharmaceutical knowledge which describes the most stable elements that make it possible to formulate an adequate definition of the “drug supply” definition.","PeriodicalId":20031,"journal":{"name":"Pharmacology & Pharmacy","volume":"141 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80079985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
POLYPHARMACY IN MANAGMENT OF IN-PATIENTS WITH NOVEL CORONAVIRUS DISEASE (COVID-19) 新型冠状病毒病(covid-19)住院患者的综合用药管理
Pub Date : 2022-07-24 DOI: 10.19163/2307-9266-2022-10-3-267-277
V. Petrov, A. Ryazanova, N. S. Privaltseva, D. A. Nekrasov
The aim. To identify polypharmacy cases and develop the ways to optimize pharmacotherapy of patients with COVID-19 hospitalized in infectious disease facilities.Materials and methods. ATC/DDD analysis with calculation of DDDs/100 bed days and a sample analysis of 500 patients’ prescriptions were performed for presenting drug utilization statistics in the infectious disease facilities of Volgograd region, which had been reassigned to treat patients with COVID-19 in 2020 and 2021.Results. Five or more drugs were administered simultaneously in 96.8% of patients. Antibacterial drugs were in 74.3% of the analyzed prescriptions in 2020 and in 73.5% in 2021. The total consumption of antibiotics was 102.9 DDDs/100 bed-days in 2020 and 95.7 DDDs/100 bed-days in 2021. The cases of multiple administrations of biological disease modifying antirheumatic drugs and the use of cyclophosphamide have been identified. In 73.6% of prescriptions in 2020 and 85.4% of 2021, omeprazole at the dose of 40 mg per day was used (77.3 and 84.6 DDDs/100 bed-days, respectively). In 2021, there were cases of concomitant intravenous prescribing of acetylcysteine under the trade name of Fluimucil® with tableted forms of ambroxol and acetylcysteine under the name of ACC®. The cumulative consumption of hepatotoxic drugs was 269.2 DDDs/100 bed-days in 2020 and 401.5 DDDs/100 bed-days in 2021.Conclusion. Lack of drugs with proven effectiveness for treatment of COVID-19, worked-out treatment algorithms, a high mortality of patients in the hospitals led to polypragmasy, excessive prescribing of drugs in the hospitals. The prescription of antibacterial drugs, omeprazole, mucolytics, hepatotoxic drugs, immunosuppressors in infectious hospitals should be monitored by clinical pharmacologist.
的目标。发现多药病例,制定优化传染病医院新冠肺炎住院患者药物治疗的方法。材料和方法。通过ATC/DDD分析,计算DDDs/100个床位天,并对500例患者处方进行抽样分析,提供伏尔加格勒地区传染病机构2020年和2021年重新分配治疗COVID-19患者的药物利用统计数据。96.8%的患者同时使用5种及以上药物。抗菌药物在2020年和2021年的处方分析中所占比例分别为74.3%和73.5%。2020年抗生素总消费量为102.9 DDDs/100个床位日,2021年为95.7 DDDs/100个床位日。已经确定了多次施用生物疾病修饰抗风湿药物和使用环磷酰胺的病例。在2020年和2021年的处方中,73.6%和85.4%的处方使用奥美拉唑,剂量为40 mg / d(分别为77.3和84.6 DDDs/100床日)。在2021年,出现了以Fluimucil®为商标名的乙酰半胱氨酸与以ACC®为商标名的氨溴索和乙酰半胱氨酸片剂同时静脉处方的病例。2020年肝毒性药物累计用量为269.2 DDDs/100床日,2021年为401.5 DDDs/100床日。缺乏治疗COVID-19的有效药物,制定的治疗算法,医院患者死亡率高,导致医院多用途,过度开药。感染性医院的抗菌药物、奥美拉唑、溶粘剂、肝毒性药物、免疫抑制剂的处方应由临床药理学家进行监测。
{"title":"POLYPHARMACY IN MANAGMENT OF IN-PATIENTS WITH NOVEL CORONAVIRUS DISEASE (COVID-19)","authors":"V. Petrov, A. Ryazanova, N. S. Privaltseva, D. A. Nekrasov","doi":"10.19163/2307-9266-2022-10-3-267-277","DOIUrl":"https://doi.org/10.19163/2307-9266-2022-10-3-267-277","url":null,"abstract":"The aim. To identify polypharmacy cases and develop the ways to optimize pharmacotherapy of patients with COVID-19 hospitalized in infectious disease facilities.Materials and methods. ATC/DDD analysis with calculation of DDDs/100 bed days and a sample analysis of 500 patients’ prescriptions were performed for presenting drug utilization statistics in the infectious disease facilities of Volgograd region, which had been reassigned to treat patients with COVID-19 in 2020 and 2021.Results. Five or more drugs were administered simultaneously in 96.8% of patients. Antibacterial drugs were in 74.3% of the analyzed prescriptions in 2020 and in 73.5% in 2021. The total consumption of antibiotics was 102.9 DDDs/100 bed-days in 2020 and 95.7 DDDs/100 bed-days in 2021. The cases of multiple administrations of biological disease modifying antirheumatic drugs and the use of cyclophosphamide have been identified. In 73.6% of prescriptions in 2020 and 85.4% of 2021, omeprazole at the dose of 40 mg per day was used (77.3 and 84.6 DDDs/100 bed-days, respectively). In 2021, there were cases of concomitant intravenous prescribing of acetylcysteine under the trade name of Fluimucil® with tableted forms of ambroxol and acetylcysteine under the name of ACC®. The cumulative consumption of hepatotoxic drugs was 269.2 DDDs/100 bed-days in 2020 and 401.5 DDDs/100 bed-days in 2021.Conclusion. Lack of drugs with proven effectiveness for treatment of COVID-19, worked-out treatment algorithms, a high mortality of patients in the hospitals led to polypragmasy, excessive prescribing of drugs in the hospitals. The prescription of antibacterial drugs, omeprazole, mucolytics, hepatotoxic drugs, immunosuppressors in infectious hospitals should be monitored by clinical pharmacologist.","PeriodicalId":20031,"journal":{"name":"Pharmacology & Pharmacy","volume":"31 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73540274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
CLINICAL AND ECONOMIC EVALUATION OF ATEZOLIZUMAB + VEMURAFENIB + COBIMETINIB COMBINATION AND NIVOLUMAB + IPILIMUMAB COMBINATION: ADMINISTRATION IN METASTATIC MELANOMA TREATMENT WITH BRAF-CONFIRMED MUTATION IN ADULT PATIENTS atezolizumab + vemurafenib + cobimetinib联合和nivolumab + ipilimumab联合的临床和经济评价:转移性黑色素瘤治疗成人患者braf确认突变
Pub Date : 2022-07-24 DOI: 10.19163/2307-9266-2022-10-3-278-288
I. Krysanov, E. Makarova, V. Ermakova
The aim of the study was to conduct a pharmacoeconomic evaluation of the atezolizumab, vemurofenib and cobimetinib (ATZ+VM+COB) combination and the nivolumab and ipilimumab (NIVO+IPI) combination for the treatment of BRAF-confirmed metastatic melanoma in adult patients.Materials and methods. With the help of mathematical modeling methods, a pharmacoeconomic “cost-effectiveness” analysis; a “budget impact” analysis; a sensitivity analysis to the changes in the initial parameters of the model, were carried out.Results. The analysis of literature sources made it possible to conclude that the combination of ATZ+VM+COB compared with the combination of NIVO+IPI (15.1 and 11.2 months, respectively) has a greater clinical efficacy in terms of a progression-free survival (PFS) in patients with metastatic melanoma. When choosing the ATZ+VM+COB combination, the total cost of treatment for one adult patient with metastatic melanoma per course was lower, compared to the NIVO+IPI combination (RUB 8 326 864.89 vs RUB 7 172 751.68); the difference amounted to 1 154 113.21 rubles. When calculating the “cost-effectiveness” ratio for a year of a progression-free survival, the advantage of the ATZ + VM + COB combination in comparison with the NIVO + IPI combination, remained (5 700 200.01 rubles vs 8 942 400.10 rubles); the difference amounted to 3 242 200.09 rubles. The sensitivity analysis demonstrated the developed model stability to an increase in the cost of the ATZ + VM + COB course up to + 16%, a decrease in the cost of the NIVO + IPI course to –13%, and a reduction in the PFS to –37% against the background of the ATZ + VM + COB course. The “budget impact” analysis showed the possibility of reducing costs by 8 655 849.11 rubles with an increase from 5% to 20% in the proportion of the patients administrated with the ATZ+VM+COB combination, and with a decrease from 95% to 80% in the proportion of the patients administrated with the NIVO+IPI combination.Conclusion. The results of the work have shown that within the healthcare system of the Russian Federation, the triple combination of ATZ+VM+COB is a clinically cost-effective option for the treatment of adult metastatic melanoma patients with a confirmed BRAF mutation.
该研究的目的是对atezolizumab, vemurofenib和cobimetinib (ATZ+VM+COB)组合以及nivolumab和ipilimumab (NIVO+IPI)组合治疗成人braf确诊的转移性黑色素瘤进行药物经济学评估。材料和方法。借助数学建模方法,进行药物经济学“成本-效果”分析;“预算影响”分析;对模型初始参数的变化进行了敏感性分析。通过对文献资料的分析,我们可以得出结论,ATZ+VM+COB联合治疗比NIVO+IPI联合治疗(分别为15.1个月和11.2个月)在转移性黑色素瘤患者的无进展生存期(PFS)方面具有更大的临床疗效。当选择ATZ+VM+COB联合治疗时,与NIVO+IPI联合治疗相比,一名成年转移性黑色素瘤患者每疗程的总治疗成本更低(8 326 864.89卢布vs 7 172 751.68卢布);差额为1 154 113.21卢布。在计算无进展生存期一年的“成本效益”比率时,与NIVO + IPI组合相比,ATZ + VM + COB组合的优势仍然存在(5 700 200.01卢布对8 942 400.10卢布);差额为3 242 200.09卢布。敏感性分析表明,在ATZ + VM + COB过程的背景下,开发的模型稳定性可以将ATZ + VM + COB过程的成本增加到+ 16%,将NIVO + IPI过程的成本降低到-13%,将PFS降低到-37%。“预算影响”分析显示,ATZ+VM+COB联合用药的患者比例从5%增加到20%,NIVO+IPI联合用药的患者比例从95%减少到80%,可降低成本8 655 849.11卢布。研究结果表明,在俄罗斯联邦的医疗保健系统内,ATZ+VM+COB的三联疗法是治疗确诊BRAF突变的成人转移性黑色素瘤患者的临床成本效益选择。
{"title":"CLINICAL AND ECONOMIC EVALUATION OF ATEZOLIZUMAB + VEMURAFENIB + COBIMETINIB COMBINATION AND NIVOLUMAB + IPILIMUMAB COMBINATION: ADMINISTRATION IN METASTATIC MELANOMA TREATMENT WITH BRAF-CONFIRMED MUTATION IN ADULT PATIENTS","authors":"I. Krysanov, E. Makarova, V. Ermakova","doi":"10.19163/2307-9266-2022-10-3-278-288","DOIUrl":"https://doi.org/10.19163/2307-9266-2022-10-3-278-288","url":null,"abstract":"The aim of the study was to conduct a pharmacoeconomic evaluation of the atezolizumab, vemurofenib and cobimetinib (ATZ+VM+COB) combination and the nivolumab and ipilimumab (NIVO+IPI) combination for the treatment of BRAF-confirmed metastatic melanoma in adult patients.Materials and methods. With the help of mathematical modeling methods, a pharmacoeconomic “cost-effectiveness” analysis; a “budget impact” analysis; a sensitivity analysis to the changes in the initial parameters of the model, were carried out.Results. The analysis of literature sources made it possible to conclude that the combination of ATZ+VM+COB compared with the combination of NIVO+IPI (15.1 and 11.2 months, respectively) has a greater clinical efficacy in terms of a progression-free survival (PFS) in patients with metastatic melanoma. When choosing the ATZ+VM+COB combination, the total cost of treatment for one adult patient with metastatic melanoma per course was lower, compared to the NIVO+IPI combination (RUB 8 326 864.89 vs RUB 7 172 751.68); the difference amounted to 1 154 113.21 rubles. When calculating the “cost-effectiveness” ratio for a year of a progression-free survival, the advantage of the ATZ + VM + COB combination in comparison with the NIVO + IPI combination, remained (5 700 200.01 rubles vs 8 942 400.10 rubles); the difference amounted to 3 242 200.09 rubles. The sensitivity analysis demonstrated the developed model stability to an increase in the cost of the ATZ + VM + COB course up to + 16%, a decrease in the cost of the NIVO + IPI course to –13%, and a reduction in the PFS to –37% against the background of the ATZ + VM + COB course. The “budget impact” analysis showed the possibility of reducing costs by 8 655 849.11 rubles with an increase from 5% to 20% in the proportion of the patients administrated with the ATZ+VM+COB combination, and with a decrease from 95% to 80% in the proportion of the patients administrated with the NIVO+IPI combination.Conclusion. The results of the work have shown that within the healthcare system of the Russian Federation, the triple combination of ATZ+VM+COB is a clinically cost-effective option for the treatment of adult metastatic melanoma patients with a confirmed BRAF mutation.","PeriodicalId":20031,"journal":{"name":"Pharmacology & Pharmacy","volume":"4 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84907041","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
OPTIMIZATION TECHNOLOGY OF FAT-SOLUBLE VITAMINS PRODUCTION BASED ON ALKALINE HYDROLYSIS 基于碱水解的脂溶性维生素生产工艺优化
Pub Date : 2022-07-24 DOI: 10.19163/2307-9266-2022-10-3-255-266
E. B. Sysuev, E. Stepanova, V. D. Noskova
In the group of fat-soluble vitamins, vitamin D is one of the most relevant objects, that is why the problem of its technology optimization is under consideration. In general, there is a number of ways to obtain this substance, although it is not produced in Russia yet.The aim of the study was to select optimal process conditions to increase the efficiency of protein transformation with the isolation of a fat fraction containing fat-soluble vitamin D.Materials and methods. Various types of fish and the vitamins contained in them are described as the main research models. Variants of technological solutions have been considered: the possibility of using extraction to obtain the vitamin D substance has been tested. Classical maceration and intensifying maceration have been used; the circulating extraction method and the alkaline hydrolysis method have been applied. The yield of the target product has been determined by HPLC.Results. Methods for obtaining the substance of fat-soluble vitamin D from fish raw materials have been considered in detail. The optimal technological characteristics of the vitamin release by alkaline hydrolysis with a 12.5% decrease in the concentration of the hydrolyzing alkaline component – potassium hydroxide – has been established; that concentration ensured the maximum yield of the fat fraction containing vitamin D.Conclusion. The use of the resulting substance makes it possible to develop domestic standard samples applicable both in the pharmaceutical field and in the field of technical regulation.
在脂溶性维生素组中,维生素D是最相关的对象之一,因此其工艺优化问题正在考虑之中。一般来说,有许多方法可以获得这种物质,尽管它还没有在俄罗斯生产。研究的目的是选择最佳的工艺条件,以提高含脂溶性维生素d的脂肪部分的蛋白质转化效率。以各类鱼类及其所含维生素为主要研究模型。已经考虑了各种技术解决方案:已经测试了使用提取获得维生素D物质的可能性。采用经典浸渍法和强化浸渍法;采用了循环萃取法和碱水解法。用高效液相色谱法测定了目标产物的收率。研究了从鱼类原料中提取脂溶性维生素D的方法。确定了在水解碱性组分氢氧化钾浓度降低12.5%的条件下碱性水解维生素的最佳工艺特征;该浓度可保证含维生素d脂肪部分的最大产率。所得物质的使用使开发既适用于制药领域又适用于技术法规领域的国内标准样品成为可能。
{"title":"OPTIMIZATION TECHNOLOGY OF FAT-SOLUBLE VITAMINS PRODUCTION BASED ON ALKALINE HYDROLYSIS","authors":"E. B. Sysuev, E. Stepanova, V. D. Noskova","doi":"10.19163/2307-9266-2022-10-3-255-266","DOIUrl":"https://doi.org/10.19163/2307-9266-2022-10-3-255-266","url":null,"abstract":"In the group of fat-soluble vitamins, vitamin D is one of the most relevant objects, that is why the problem of its technology optimization is under consideration. In general, there is a number of ways to obtain this substance, although it is not produced in Russia yet.The aim of the study was to select optimal process conditions to increase the efficiency of protein transformation with the isolation of a fat fraction containing fat-soluble vitamin D.Materials and methods. Various types of fish and the vitamins contained in them are described as the main research models. Variants of technological solutions have been considered: the possibility of using extraction to obtain the vitamin D substance has been tested. Classical maceration and intensifying maceration have been used; the circulating extraction method and the alkaline hydrolysis method have been applied. The yield of the target product has been determined by HPLC.Results. Methods for obtaining the substance of fat-soluble vitamin D from fish raw materials have been considered in detail. The optimal technological characteristics of the vitamin release by alkaline hydrolysis with a 12.5% decrease in the concentration of the hydrolyzing alkaline component – potassium hydroxide – has been established; that concentration ensured the maximum yield of the fat fraction containing vitamin D.Conclusion. The use of the resulting substance makes it possible to develop domestic standard samples applicable both in the pharmaceutical field and in the field of technical regulation.","PeriodicalId":20031,"journal":{"name":"Pharmacology & Pharmacy","volume":"25 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77036961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
PHYTOCHEMICAL AND MICROBIOLOGICAL ASPECTS OF THE NIGELLA SATIVA L. HERBS STUDY 黑草草本植物化学和微生物学研究
Pub Date : 2022-07-24 DOI: 10.19163/2307-9266-2022-10-3-244-254
A. Mubinov, V. Kurkin, E. Avdeeva, S. D. Kolpakova, A. Zhestkov
Nigella sativa L. is a promising plant object, herbal medicinal raw materials of which can be comprehensively used for the development of drugs with an antimicrobial activity.The aim of the study was to screen and compare the antimicrobial activity of water-ethanolic extractions from the Nigella sativa L. herbs with a eucalyptus tincture of as a reference preparation.Materials and methods. Chromatograms of the extracts were obtained by thin layer chromatography in the system of chloroform – ethanol – water (26:16:3). The detection of adsorption zones was carried out in daylight, in the UV light at λ=254 nm and λ=365 nm, as well as by treatment with reagents – a 3% alcohol solution of aluminum chloride and a solution of diazobenzosulfonic acid in a 20% sodium carbonate solution. The next step was to determine the minimum inhibitory concentration by the method of double serial dilutions in Mueller-Hinton nutrient broth (Bio-Rad, USA). As test cultures, the strains of the American Type Culture Collection (ATCC) microorganisms were used: Staphylococcus aureus (ATCC 29213), Escherichia coli (ATCC 25922), Pseudomonas aeruginosa (ATCC 27853), as well as Candida albicans (a clinical strain). Simultaneously, an experiment to establish a “negative” control was carried out. For the comparative evaluation of the studied samples activity, its activity was compared with the reference preparation with a proven antimicrobial activity – a eucalyptus tincture.Results. For all water-ethanolic extractions and the Nigella sativa L. herb tincture, the adsorption zones characteristic of flavonoids with Rf1 = 0.28, Rf2 = 0.15, Rf3 = 0.11 were revealed, and under the action of an alcoholic solution of aluminum chloride, the fluorescence of the adsorption zones was also enhanced, which indicates the phenolic nature of these compounds.In the course of the study, it was found out that all water-ethanolic extractions from the Nigella sativa L. herbs have the greatest antimicrobial effect against the Pseudomonas aeruginosa strain. When compared with the reference preparation – a eucalyptus tincture, it was notified that the specified tincture of the Nigella sativa L. herbs has an advantage in the antimicrobial activity over the strain of Pseudomonas aeruginosa – the action at the 16-fold dilution vs the 4-fold dilution. The action on the Escherichia coli and Candida albicans strains is comparable for the both tinctures.Conclusion. The obtained results of phytochemical and microbiological analyses will be used as a rationale for the introduction of antimicrobial preparations based on the Nigella sativa herbs in medical and pharmaceutical practice.
黑草(Nigella sativa L.)是一种很有发展前途的植物,其中草药原料可以综合利用,开发具有抗菌活性的药物。本研究的目的是筛选和比较黑草草本植物水乙醇提取物和桉树酊剂作为对照制剂的抗菌活性。材料和方法。在氯仿-乙醇-水(26:16:3)体系中,用薄层色谱法得到提取物的色谱图。在日光、λ=254 nm和λ=365 nm的紫外光下,以及用3%乙醇氯化铝溶液和20%碳酸钠溶液中的重氮苯磺酸溶液处理,对吸附区进行了检测。下一步是在Mueller-Hinton营养液(Bio-Rad, USA)中采用双串联稀释法测定最低抑菌浓度。试验培养采用美国型培养收集(American Type Culture Collection, ATCC)微生物菌株:金黄色葡萄球菌(ATCC 29213)、大肠杆菌(ATCC 25922)、铜绿假单胞菌(ATCC 27853)和白色念珠菌(临床菌株)。同时,进行了建立“阴性”对照的实验。为了对所研究样品的活性进行比较评价,将其活性与具有抗菌活性的对照制剂-桉树酊剂进行了比较。所有水乙醇提取液和黑草草本酊剂均显示出Rf1 = 0.28、Rf2 = 0.15、Rf3 = 0.11时黄酮类化合物的吸附区特征,且在氯化铝醇溶液的作用下,吸附区的荧光增强,表明这些化合物具有酚类性质。在研究过程中,我们发现黑皮草中草药的水乙醇提取物对铜绿假单胞菌的抑菌效果最好。当与参比制剂(桉树酊剂)进行比较时,通知指定的黑鬼草(Nigella sativa L.)草药酊剂在抗菌活性方面优于铜绿假单胞菌菌株-在16倍稀释时的作用优于4倍稀释时的作用。两种酊剂对大肠杆菌和白色念珠菌的作用具有可比性。获得的植物化学和微生物分析结果将被用作在医疗和制药实践中引入基于黑草草药的抗菌制剂的基本原理。
{"title":"PHYTOCHEMICAL AND MICROBIOLOGICAL ASPECTS OF THE NIGELLA SATIVA L. HERBS STUDY","authors":"A. Mubinov, V. Kurkin, E. Avdeeva, S. D. Kolpakova, A. Zhestkov","doi":"10.19163/2307-9266-2022-10-3-244-254","DOIUrl":"https://doi.org/10.19163/2307-9266-2022-10-3-244-254","url":null,"abstract":"Nigella sativa L. is a promising plant object, herbal medicinal raw materials of which can be comprehensively used for the development of drugs with an antimicrobial activity.The aim of the study was to screen and compare the antimicrobial activity of water-ethanolic extractions from the Nigella sativa L. herbs with a eucalyptus tincture of as a reference preparation.Materials and methods. Chromatograms of the extracts were obtained by thin layer chromatography in the system of chloroform – ethanol – water (26:16:3). The detection of adsorption zones was carried out in daylight, in the UV light at λ=254 nm and λ=365 nm, as well as by treatment with reagents – a 3% alcohol solution of aluminum chloride and a solution of diazobenzosulfonic acid in a 20% sodium carbonate solution. The next step was to determine the minimum inhibitory concentration by the method of double serial dilutions in Mueller-Hinton nutrient broth (Bio-Rad, USA). As test cultures, the strains of the American Type Culture Collection (ATCC) microorganisms were used: Staphylococcus aureus (ATCC 29213), Escherichia coli (ATCC 25922), Pseudomonas aeruginosa (ATCC 27853), as well as Candida albicans (a clinical strain). Simultaneously, an experiment to establish a “negative” control was carried out. For the comparative evaluation of the studied samples activity, its activity was compared with the reference preparation with a proven antimicrobial activity – a eucalyptus tincture.Results. For all water-ethanolic extractions and the Nigella sativa L. herb tincture, the adsorption zones characteristic of flavonoids with Rf1 = 0.28, Rf2 = 0.15, Rf3 = 0.11 were revealed, and under the action of an alcoholic solution of aluminum chloride, the fluorescence of the adsorption zones was also enhanced, which indicates the phenolic nature of these compounds.In the course of the study, it was found out that all water-ethanolic extractions from the Nigella sativa L. herbs have the greatest antimicrobial effect against the Pseudomonas aeruginosa strain. When compared with the reference preparation – a eucalyptus tincture, it was notified that the specified tincture of the Nigella sativa L. herbs has an advantage in the antimicrobial activity over the strain of Pseudomonas aeruginosa – the action at the 16-fold dilution vs the 4-fold dilution. The action on the Escherichia coli and Candida albicans strains is comparable for the both tinctures.Conclusion. The obtained results of phytochemical and microbiological analyses will be used as a rationale for the introduction of antimicrobial preparations based on the Nigella sativa herbs in medical and pharmaceutical practice.","PeriodicalId":20031,"journal":{"name":"Pharmacology & Pharmacy","volume":"48 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83114963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Pharmacology & Pharmacy
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1